Differences in immunogenicity of HLA antigens and the impact of cross-reactivity on the humoral response

Transplantation

Volumn 99, Issue 1, 2015, Pages 77-85

  Lucas, Donna P ^a   Leffell, Mary S ^a   Zachary, Andrea A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA A ANTIGEN; HLA ANTIGEN; HLA B ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN; HLA DRB1 ANTIGEN; ALLOANTIBODY; EPITOPE;

ANTIGEN SPECIFICITY; ARTICLE; BLACK PERSON; CAUCASIAN; CROSS REACTION; FEMALE; HUMAN; IMMUNOASSAY; IMMUNOGENICITY; INCIDENCE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTIPLEXED BEAD ASSAY; PHENOTYPE; RACE DIFFERENCE; SEX DIFFERENCE; ADVERSE EFFECTS; AFRICAN AMERICAN; BLOOD; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TEST; HUMORAL IMMUNITY; IMMUNOLOGY; IMMUNOPHENOTYPING; PREDICTIVE VALUE; TREATMENT OUTCOME; UNITED STATES;

AFRICAN AMERICANS; BALTIMORE; CROSS REACTIONS; EPITOPES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNITY, HUMORAL; IMMUNOPHENOTYPING; ISOANTIBODIES; KIDNEY TRANSPLANTATION; MALE; PHENOTYPE; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME;

EID: 84920189884     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000355     Document Type: Article

References (23)

1. Akalin E, Pasqual M. Sensitization after kidney transplantation. Clin J Am Soc Nephrol 2006;1:443.
2. Valenzuela NM, McNamara JT, Reed EF. Antibody-mediated graft injury: complement-dependent and complement-independent mechanisms. Curr Opin Organ Transplant 2014;19:33.
3. Yamanaga S, Watarai Y, Yamamoto T, et al. Frequent development of subclinical chronic antibody-mediated rejection within 1 year after renal transplantation with pre-transplant positive donor-specific antibodies and negative CDC crossmatches. Hum Immunol 2013;74:1111.
4. Lachmann N, Terasaki PI, Budde K, et al. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation 2009;87:1505.
5. Iyer HS, Jackson AM, Zachary AA, et al. Transplanting the highly sensitized patient: trials and tribulations. Curr Opin Nephrol Hypertens 2013;22:681.
6. Gralla J, Tong S,Wiseman AC. The impact of human leukocyte antigen mismatching on sensitization rates and subsequent retransplantation after first graft failure in pediatric renal transplant recipients. Transplantation 2013;95:1218.
7. Zachary AA, Hart JM, Lucas DP, et al. The cost of mismatching. In: Cecka JM, Terasaki PI, eds. Clinical Transplants 2007. Los Angeles: Terasaki Foundation; 2008: 261.
8. Dankers MKA, Witvliet MD, Roelen DL, et al. The number of amino acid triplet differences between patient and donor is predictive for the antibody reactivity against mismatched human leukocyte antigens. Transplantation 2004;77:1236.
9. Duquesnoy RJ. A structurally based approach to determine HLA compatibility at the humoral immune level. Hum Immunol 2006;67:847.
10. Akkoc N, Scornik JC. HLA epitope matching. Contribution of matched residues to epitopes recognized by alloantibodies. Transplantation 1991;52:903.
11. Mariuzza RA, Phillips SE, Poljak RJ. The structural basis of antigenantibody recognition. Annu Rev Biophys Biophys Chem 1987;16:139
12. Kosmoliaptsis V, Dafforn TR, Chaudhry AN, et al. High-resolution, threedimensional modeling of human leukocyte antigen class I structure and surface electrostatic potential reveals the molecular basis for alloantibody binding epitopes. Hum Immunol 2011;72:1049.
13. Duquesnoy RJ, Claas FHJ. 14th International HLA and Immunogenetics Workshop: report on the structural basis of HLA compatibility. Tissue Antigens 2007;69s1:180.
14. El-Awar N, Terasaki PI, Cai J, et al. Epitopes of the HLA-A, B, C, DR, DQ and MICA antigens. In: Cecka JM, Terasaki PI, eds. Clinical Transplants 2007. Los Angeles: Terasaki Foundation; 2008: 175.
15. Duquesnoy RJ, Marrari M. Correlations between Terasaki's HLA class I epitopes and HLAMatchmaker-defined eplets on HLA-A,-B and-C antigens. Tissue Antigens 2009;74:117.
16. Rodey GE, Revels K, Fuller TC. Epitope specificity of HLA class I alloantibodies: I. Frequency analysis of antibodies to private versus public specificities in potential transplant recipients. Transplantation 1994;39:272.
17. Singh D, Kiberd BA, West KA, et al. Importance of peak PRA in predicting the kidney transplant survival in highly sensitized patients. Transplant Proc 2003;35:2395.
18. Baron C, Pastural M, Lang P, et al. Long-term kidney graft survival across a positive historic but negative current sensitized cross-match. Transplantation 2002;73:232.
19. Avlonitis VS, Chidambaram V, Manas DM, et al. The relevance of donor T cell-directed immunoglobulin G in historic sera in the age of flow cytometry. Transplantation 2000;70:1260.
20. Crowe DO. The effect of cross-reactive epitope group matching on allocation and sensitization. Clin Transplant 2003;17s9:13.
21. Dankers MKA, Roelen DL, van der Meer-Prins EMW, et al. Differential immunogenicity of HLA mismatches: HLA-A2 versus HLA-A28. Transplantation 2003;75:418.
22. Kosmoliaptsis V, Sharples LD, Chaudhry AN, et al. Predicting HLA class II alloantigen immunogenicity from the number and physiochemical properties of amino acid polymorphisms. Transplantation 2011;91: 183.
23. Hwang S-H, Oh H-B, Shin E-S, et al. Influence of mismatching of HLA cross-reactive groups on cadaveric kidney transplantation. Transplant Proc 2005;37:4194.